Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK

Current Medical Research and Opinion

Volumn 21, Issue 6, 2005, Pages 817-826

  Guest, Julian F ^a   Davie, Alison M ^a   Clegg, John P ^a  

^a CATALYST Health Economics Consultants   (United Kingdom)

Author keywords

Cilostazol; Costs; Intermittent claudication; Naftidrofuryl; Pentoxifylline; UK

Indexed keywords

CILOSTAZOL; NAFTIDROFURYL; PENTOXIFYLLINE;

ADULT; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; HUMAN; INTERMITTENT CLAUDICATION; LEG; MODEL; PERIPHERAL OCCLUSIVE ARTERY DISEASE; SYMPTOMATOLOGY; TREATMENT OUTCOME; UNITED KINGDOM; WALKING;

ADULT; COST-BENEFIT ANALYSIS; GREAT BRITAIN; HUMANS; INTERMITTENT CLAUDICATION; NAFRONYL; PENTOXIFYLLINE; STATE MEDICINE; TETRAZOLES; VASODILATOR AGENTS; WALKING;

EID: 21244470325     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X41471     Document Type: Article

References (36)

1. Golledge J, Garratt A, Greenhalg RM, et al. Patient-assessed health outcomes in peripheral arterial disease. Eur J Vasc Endovasc Surg 2000;19:109-10
2. Fowkes FG, Housley E, Cawood EH, et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991;20:384-92
3. Bevan EG, Waller PC, Ramsay LE. Pharmacological approaches to the treatment of intermittent claudication. Drugs Aging 1992;2:125-36
4. Pell JP. Impact of intermittent claudication on quality of life. The Scottish Vascular Audit Group. Eur J Vasc Endovasc Surg 1995;9:469-72
5. Crosby FE, Ventura MR, Frainier MA, et al. Well-being and concerns of patients with peripheral arterial occlusive disease. J Vasc Nurs 1993;11:5-11
6. Intercontinental Medical Statistics data set specific for UK. Intercontinental Medical Statistics Ltd, Middlesex, UK, 2003
7. Chapman TM, Goa KL. Cilostazol: a review of its use in intermittent claudication. Am J Cardiovasc Drugs 2003;3:117-38
8. Thompson PD, Zimet R, Forbes WP, et al. Meta-analysis of results from eight randomised, placebo-controlled trails on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002;90:1314-19
9. Cariski A. Cilostazol: a novel treatment option in intermittent claudication. Int J Clin Prac Suppl 2001;119:11-8
10. Lehert P, Comte S, Gamand S, et al. Naftidrofuryl in intermittent claudication: a retrospective analysis. Cardiovasc Pharmacol 1994;23(Suppl 3):S48-52
11. Cameron HA, Waller PC, Ramsay LE. Drug treatment of intermittent claudication: a critical analysis of the methods and findings of published clinical trials, 1965-1985. Br J Clin Pharmacol 1988;26:569-76
12. Green RM, McNamara J. The effects of pentoxifylline on patients with intermittent claudication. J Vasc Surg 1988;7:356-62
13. AbuRahma AF, Woodruff BA. Effects and limitations of pentoxifylline therapy in various stages of peripheral vascular disease of the lower extremity. Am J Surg 1990;160:266-70
14. Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999;159:2041-50
15. Strandness DE, Dalman RL, Panian S, et al. Effect of cilostazol in patients with intermittent claudication: a randomised, double-blind, placebo-controlled study. Vasc Endovasc Surg 2002;36:83-91
16. Adhoute G, Andreassian B, Boccalon H, et al. Treatment of stage II chronic arterial disease of the lower limbs with the serotonergic antagonist naftidrofuryl: results after 6 months of a controlled, multicenter study. J Cardiovasc Pharmacol 1990;16(Suppl 3):S75-80
17. Kieffer E, Bahnini A, Mouren X, et al. A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication. Findings of the Naftidrofuryl Clinical Ischemia Study (NCIS). Int Angiol 2001;20:58-65
18. Moody AP, al-Khaffaf HS, Lehert P, et al. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl. J Cardiovasc Pharmacol 1994;23(Suppl 3):S44-7
19. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000;109:523-30
20. Porter JM, Cutler BS, Lee BY, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 1982;104:66-72
21. Lindgarde F, Jelnes R, Bjorkman H, et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Scandinavian Study Group. Circulation 1989;80:1549-56
22. NHS 2003 Reference Costs. Department of Health, London, 2004
23. Monthly Index of Medical Specialites 2003 editions. London: Haymarket Publications Ltd
24. Netten A, Curtis L. Unit costs of health and social care 2003. University of Kent, Canterbury. Personal Social Services Research Unit 2003
25. Drug Tariff 2003. Available from http://www.drugtariff.com
26. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. NEJM 2001;344:1608-19
27. Hiatt WR. New treatment options in intermittent claudication: the US experience. Int J Clin Prac Suppl 2001;119:20-8
28. Radack K, Wyderski RJ. Conservative management of intermittent claudication. Annals Int Med 1990;113:135-46
29. Gillings DB. Pentoxifylline and intermittent claudication: review of clinical trials and cost-effectiveness analyses. Cardiovasc Pharmacol 1995;25(Suppl 2):S44-50
30. De Vries SO, Visser K, de Vries JA, et al. Intermittent claudication: cost effectiveness of revascularization versus exercise therapy. Radiology 2002;222:25-36
31. Savage P, Ricci MA, Lynn M, et al. Effects of home versus supervised exercise for patients with intermittent claudication. Cardiopulm Rehabil 2001;21:152-7
32. Troeng T, Bergqvist D, Janzon L, et al. The choice of strategy in the treatment of intermittent claudication - a decision tree approach. Eur J Vasc Surg 1993;7:438-43
33. Hunink MG, Wong JB, Donaldson MC, et al. Revascularization for femoropopliteal disease. A decision and cost-effectiveness analysis. JAMA 1995;274:165-71
34. Weinstein MC, Fineberg HV. Clinical decision analysis. Philadelphia: WB Saunders Co., 1980; p.228-65
35. Boccalon H, Lehert P, Mosnier M. Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication. Ann Cardiol Angeiol (Paris) 2001;50:175-82
36. Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. Vasc Surg 1998;27:267-74; discussion 274-5